This week the FDA approved a form of fentanyl that can be administered through the buccal mucosa — but its label carries boxed warnings. And two weeks ago, the opioid propoxyphene got boxed warnings on its Darvon and Darvocet formulations. The FDA is trying to regulate the opioids more closely, reminding prescribers and users of the dangers they pose. In February, after another FDA announcement on opioid control, we interviewed Dr. Roger Chou of Oregon Health Sciences University on this topic.

Since it’s summer and the news is relatively scant, I’m reprising the interview and skipping the news summary.

Enough said!

This week’s links:

Older links:

The post Podcast 50: A re-podcast of an interview from February regarding the FDA’s plans for tightening regulations on opioid use. first appeared on Clinical Conversations.